We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An update from Pfizer and Allergan on their proposed megamerger provides more insight into how Allergan product lines will be worked into Pfizer’s operating structure and various executive assignments. Read More
According to the letter, Monmouth’s IRB did not provide sufficient scrutiny to pediatric research, and conducted business without a quorum of members. Read More
England’s Department of Health and NHS England have failed to manage the Cancer Drug Fund effectively by not carrying out its intended purpose and significantly outspending its budget, according to a report released by the UK Parliament’s House of Commons. Read More
Massachusetts Attorney General Maura Healey is mulling legal action against Gilead Sciences over its sky-high prices for two hepatitis C medications, alleging that the company’s approach could violate the state’s antitrust laws. Read More
The war on high pharmaceutical prices continues, with PBM Express Scripts taking aim at what it calls an excessive price jump for Valeant Pharmaceuticals’ diabetes drug Glumetza. Read More
With 12 nations signing off on the Trans-Pacific Partnership on Wednesday, the clock has started on ratification of the treaty providing up to eight years of exclusivity for biologics. Read More
The FDA is re-examining its approval, REMS and postmarket policies for opioids in response to a growing abuse epidemic and calls to action from lawmakers. Read More